
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$281.01M
Market Cap
8.56
P/E Ratio
0.64
EPS
$7.54
52 Week High
$3.93
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2.9M |
| Total Revenue | $0 |
| Cost Of Revenue | $2.9M |
| Costof Goods And Services Sold | $2.9M |
| Operating Income | -$64M |
| Selling General And Administrative | $30M |
| Research And Development | $34M |
| Operating Expenses | $61M |
| Investment Income Net | - |
| Net Interest Income | $38K |
| Interest Income | $4.2M |
| Interest Expense | $4.2M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.9M |
| Income Before Tax | -$64M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$64M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$60M |
| Ebitda | -$57M |
| Net Income | -$64M |
| Field | Value (USD) |
|---|---|
| Total Assets | $109M |
| Total Current Assets | $101M |
| Cash And Cash Equivalents At Carrying Value | $23M |
| Cash And Short Term Investments | $23M |
| Inventory | - |
| Current Net Receivables | $1.7M |
| Total Non Current Assets | $8.1M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $74M |
| Other Current Assets | $1.5M |
| Other Non Current Assets | - |
| Total Liabilities | $65M |
| Total Current Liabilities | $17M |
| Current Accounts Payable | $3.4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $6.7M |
| Total Non Current Liabilities | $48M |
| Capital Lease Obligations | $4.1M |
| Long Term Debt | $13M |
| Current Long Term Debt | $5.9M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $23M |
| Other Current Liabilities | $6.4M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $44M |
| Treasury Stock | - |
| Retained Earnings | -$813M |
| Common Stock | $457K |
| Common Stock Shares Outstanding | $41M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$56M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.9M |
| Capital Expenditures | $2.4M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$39M |
| Cashflow From Financing | $104M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$64M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2.9M |
| Total Revenue | $0 |
| Cost Of Revenue | $2.9M |
| Costof Goods And Services Sold | $2.9M |
| Operating Income | -$64M |
| Selling General And Administrative | $30M |
| Research And Development | $34M |
| Operating Expenses | $61M |
| Investment Income Net | - |
| Net Interest Income | $38K |
| Interest Income | $4.2M |
| Interest Expense | $4.2M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.9M |
| Income Before Tax | -$64M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$64M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$60M |
| Ebitda | -$57M |
| Net Income | -$64M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in New York, NY, specializing in the development of gene and cell therapies aimed at addressing rare, life-threatening genetic disorders. The company is committed to innovating therapeutic solutions through its proprietary technologies and extensive clinical development pipeline, targeting significant unmet medical needs. With a focus on improving patient outcomes, Abeona strives to redefine the field of genetic therapies and create a comprehensive portfolio of treatment options for patients facing severe health challenges.